• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

功能性 siRNA 试剂的分子工程。

Molecular Engineering of Functional SiRNA Agents.

机构信息

Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, California 95817, United States.

出版信息

ACS Synth Biol. 2024 Jun 21;13(6):1906-1915. doi: 10.1021/acssynbio.4c00181. Epub 2024 May 11.

DOI:10.1021/acssynbio.4c00181
PMID:38733599
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11197084/
Abstract

Synthetic biology constitutes a scientific domain focused on intentional redesign of organisms to confer novel functionalities or create new products through strategic engineering of their genetic makeup. Leveraging the inherent capabilities of nature, one may address challenges across diverse sectors including medicine. Inspired by this concept, we have developed an innovative bioengineering platform, enabling high-yield and large-scale production of biological small interfering RNA (BioRNA/siRNA) agents via bacterial fermentation. Herein, we show that with the use of a new tRNA fused pre-miRNA carrier, we can produce various forms of BioRNA/siRNA agents within living host cells. We report a high-level overexpression of nine target BioRNA/siRNA molecules at 100% success rate, yielding 3-10 mg of BioRNA/siRNA per 0.25 L of bacterial culture with high purity (>98%) and low endotoxin (<5 EU/μg RNA). Furthermore, we demonstrate that three representative BioRNA/siRNAs against GFP, BCL2, and PD-L1 are biologically active and can specifically and efficiently silence their respective targets with the potential to effectively produce downstream antiproliferation effects by PD-L1-siRNA. With these promising results, we aim to advance the field of synthetic biology by offering a novel platform to bioengineer functional siRNA agents for research and drug development.

摘要

合成生物学是一个专注于通过对生物体的基因结构进行战略性工程设计,来赋予其新功能或创造新产品的科学领域。利用自然的固有能力,人们可以解决包括医学在内的各个领域的挑战。受这一概念的启发,我们开发了一种创新的生物工程平台,通过细菌发酵实现生物小分子干扰 RNA(BioRNA/siRNA)的高效、大规模生产。在此,我们展示了一种新的 tRNA 融合前体 miRNA 载体,它可以在活宿主细胞内产生各种形式的 BioRNA/siRNA 药物。我们报告了 9 种目标 BioRNA/siRNA 分子的高水平过表达,成功率达到 100%,每 0.25L 细菌培养物可产生 3-10mg 的 BioRNA/siRNA,纯度>98%,内毒素<5EU/μg RNA。此外,我们证明了三种针对 GFP、BCL2 和 PD-L1 的代表性 BioRNA/siRNA 是具有生物活性的,能够特异性和有效地沉默各自的靶标,并有可能通过 PD-L1-siRNA 产生有效的下游增殖抑制作用。有了这些有希望的结果,我们旨在通过提供一个新的平台来生物工程功能性 siRNA 药物,为研究和药物开发提供帮助,从而推动合成生物学领域的发展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/e4ae62e60bac/sb4c00181_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/e130c2c29e03/sb4c00181_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/2a0bc0fe6bbe/sb4c00181_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/419b80bdd5bf/sb4c00181_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/bf07167ca604/sb4c00181_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/e4ae62e60bac/sb4c00181_0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/e130c2c29e03/sb4c00181_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/2a0bc0fe6bbe/sb4c00181_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/419b80bdd5bf/sb4c00181_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/bf07167ca604/sb4c00181_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b98e/11197084/e4ae62e60bac/sb4c00181_0005.jpg

相似文献

1
Molecular Engineering of Functional SiRNA Agents.功能性 siRNA 试剂的分子工程。
ACS Synth Biol. 2024 Jun 21;13(6):1906-1915. doi: 10.1021/acssynbio.4c00181. Epub 2024 May 11.
2
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.基于 RNAi 的治疗方法和新型 RNA 生物工程技术。
J Pharmacol Exp Ther. 2023 Jan;384(1):133-154. doi: 10.1124/jpet.122.001234. Epub 2022 Jun 9.
3
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
4
Sexual Harassment and Prevention Training性骚扰与预防培训
5
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
6
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.降低男男性行为者中艾滋病毒性传播风险的行为干预措施。
Cochrane Database Syst Rev. 2008 Jul 16(3):CD001230. doi: 10.1002/14651858.CD001230.pub2.
7
Bioengineered miR-7-5p modulates non-small cell lung cancer cell metabolism to improve therapy.生物工程改造的miR-7-5p调节非小细胞肺癌细胞代谢以改善治疗效果。
Mol Pharmacol. 2025 Jan;107(1):100006. doi: 10.1016/j.molpha.2024.100006. Epub 2024 Nov 29.
8
Nucleic Acid Nanocapsules as a New Platform to Deliver Therapeutic Nucleic Acids for Gene Regulation.核酸纳米胶囊作为用于基因调控的治疗性核酸递送新平台。
Acc Chem Res. 2025 Jul 1;58(13):1951-1962. doi: 10.1021/acs.accounts.5c00126. Epub 2025 Jun 9.
9
Fabricating mice and dementia: opening up relations in multi-species research制造小鼠与痴呆症:开启多物种研究中的关联
10
How lived experiences of illness trajectories, burdens of treatment, and social inequalities shape service user and caregiver participation in health and social care: a theory-informed qualitative evidence synthesis.疾病轨迹的生活经历、治疗负担和社会不平等如何影响服务使用者和照顾者参与健康和社会护理:一项基于理论的定性证据综合分析
Health Soc Care Deliv Res. 2025 Jun;13(24):1-120. doi: 10.3310/HGTQ8159.

引用本文的文献

1
In Vivo Fermentation Production of RNA Interference Agents.RNA干扰剂的体内发酵生产
Methods Mol Biol. 2025;2965:489-500. doi: 10.1007/978-1-0716-4742-4_26.
2
Comparison of Three Computational Tools for the Prediction of RNA Tertiary Structures.用于预测RNA三级结构的三种计算工具的比较
Noncoding RNA. 2024 Nov 8;10(6):55. doi: 10.3390/ncrna10060055.

本文引用的文献

1
The Growing Class of Novel RNAi Therapeutics.新型 RNAi 治疗药物不断增加。
Mol Pharmacol. 2024 Jun 18;106(1):13-20. doi: 10.1124/molpharm.124.000895.
2
Novel RNA molecular bioengineering technology efficiently produces functional miRNA agents.新型 RNA 分子生物工程技术高效生产功能性 miRNA 制剂。
RNA. 2024 May 16;30(6):680-694. doi: 10.1261/rna.079904.123.
3
Harnessing synthetic biology for advancing RNA therapeutics and vaccine design.利用合成生物学推进 RNA 治疗学和疫苗设计。
NPJ Syst Biol Appl. 2023 Nov 30;9(1):60. doi: 10.1038/s41540-023-00323-3.
4
Applications of synthetic biology in medical and pharmaceutical fields.合成生物学在医学和制药领域的应用。
Signal Transduct Target Ther. 2023 May 11;8(1):199. doi: 10.1038/s41392-023-01440-5.
5
Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.Eplontersen开放标签3期研究NEURO-TTRansform中遗传性转甲状腺素蛋白淀粉样变性多神经病(ATTRv-PN)患者的特征
Neurol Ther. 2023 Feb;12(1):267-287. doi: 10.1007/s40120-022-00414-z. Epub 2022 Dec 16.
6
Nedosiran, a Candidate siRNA Drug for the Treatment of Primary Hyperoxaluria: Design, Development, and Clinical Studies.奈多司然,一种用于治疗原发性高草酸尿症的小干扰RNA候选药物:设计、研发及临床研究
ACS Pharmacol Transl Sci. 2022 Sep 21;5(11):1007-1016. doi: 10.1021/acsptsci.2c00110. eCollection 2022 Nov 11.
7
Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer.同时靶向细胞周期蛋白依赖性激酶2(CDK2)和细胞周期蛋白依赖性激酶4/6(CDK4/6)可克服雌激素受体阳性(ER+)乳腺癌对芳香化酶抑制剂和CDK4/6抑制剂的耐药性。
NPJ Precis Oncol. 2022 Sep 24;6(1):68. doi: 10.1038/s41698-022-00311-6.
8
Therapeutic siRNA: State-of-the-Art and Future Perspectives.治疗性 siRNA:现状与未来展望。
BioDrugs. 2022 Sep;36(5):549-571. doi: 10.1007/s40259-022-00549-3. Epub 2022 Aug 23.
9
A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells.免疫 T 细胞和癌细胞中 PD-1/PD-L1 siRNA 递呈系统的综述。
Int Immunopharmacol. 2022 Oct;111:109022. doi: 10.1016/j.intimp.2022.109022. Epub 2022 Aug 17.
10
RNA-based therapeutics: an overview and prospectus.基于 RNA 的治疗学:概述与展望。
Cell Death Dis. 2022 Jul 23;13(7):644. doi: 10.1038/s41419-022-05075-2.